T he discovery of ATP-sensitive K ϩ currents (K ATP ) offered an ideal molecular mechanism for coupling energy availability to excitability, function, and ATP consumption in myocardium, 1 as well as other excitable tissues such as pancreatic ␤ cells, 2 wherein these channels regulate excitation-secretion coupling and are targets for antidiabetic drugs like sulfonylureas. 3 With the cloning of the genes underlying K ATP channels, it became clear that these channels were comprised of heteromultimers of 4 inwardly rectifying K ϩ channels (Kir6.1 or Kir6.2) and 4 ATP-binding cassette sulfonylurea receptors (SUR1 or SUR2). 4 Importantly, K ATP channels with different molecular constituents show distinct functional and regulatory properties that correlate with the response of K ATP channels in various excitable cells, presumably to meet the diverse, and often unique, energy-sensing requirements between different tissues. For example, K ATP channels are formed almost exclusively by Kir6.2 and SUR1 genes in pancreatic ␤ cells, 4 where these channels use the relative MgADP/MgATP ratio to tightly couple subplasmamembrane glucose levels with insulin release by modulating membrane potential and thereby calcium influx. 5 By contrast, sarcolemmal K ATP channels in cardiomyocytes (as well as skeletal muscle) have been shown to be comprised primarily of coassembled Kir6.2 and SUR2A proteins. 6 Although the role of cardiac sarcolemmal K ATP channels in cardiomyocytes is incompletely understood, cardiac sarcolemmal K ATP channels appear to coordinate energy consumption with energy availability during periods of stress induced by ischemia, changes in workload, or adrenergic stimulation by modulating the action potential profile. [7] [8] [9] In addition, sarcolemmal K ATP channels also participate in the phenomenon of ischemic preconditioning, 10,11 although putative K ATP channels in the mitochondrial appear to play the dominant role. 12 Regardless, the diversity of K ATP channel function in cardiomyocytes, combined with an observed lack of correlation between K ATP channel activity and global ATP/ADP ratios in myocardium, 13, 14 suggested that other factors were involved in the regulation of K ATP in these cells. For instance, K ATP channels are constituents of macromolecular complexes containing various signaling and metabolic enzymes that are assembled into local metabolic subdomains of the cell and are postulated to monitor the energy status by measuring changes in energy flux. 15 Another obvious potential source of diversity in K ATP signaling could arise if other K ATP proteins are also constituents of cardiac sarcolemmal K ATP channels. 16 Indeed, in this issue of Circulation Research, Flagg et al 17 use mice lacking the SUR1 gene (SUR1 Ϫ/Ϫ ) to clearly establish, using an impressive combination of biochemical and electrophysical measurements along with careful analyses, that sarcolemmal K ATP channels in the atrial cardiomyocytes consist of Kir6.2 and SUR1 proteins. Furthermore, although the pharmacological results are consistent with the conclusion that ventricular K ATP channels are primarily comprised of Kir6.2 and SUR2A, it appears that low levels of SUR1 may be functionally expressed in ventricular myocytes. 17 The observation that atrial K ATP channels are comprised Kir6.2 and SUR1, the same subunits making up K ATP channels in pancreatic ␤ cells and neurons, has a number of important implications and also help to reconcile some previous observations. For instance, given its molecular composition, it is reasonable to speculate that the metabolic prerequisites for sarcolemmal K ATP activation in atrial myocytes are unique and distinct from K ATP activation in ventricular myocytes. Indeed, the authors found that dialysis of myocytes with low levels of MgATP in the recording pipette resulted in spontaneous K ATP activation in atrial, but not ventricular, myocytes, which is similar to the functional properties of K ATP currents in pancreatic ␤ cells. 2 This ease of K ATP channel activation led the authors to speculate that the activation of K ATP currents might be critical in the maintenance of atrial fibrillation, a very common condition that is associated with elevated stroke risk, reduced exercise tolerance, and bleeding complication caused by anticoagulant therapy. 18 Although this condition is primarily seen in the elderly population, it is also prevalent in patients with ventricular disease characterized by impaired pump function, in postsurgery patients, and in a subset of athletes often engaged in intense aerobic sports. 18 -20 In this scenario, enhanced atrial electric and mechanical activity associated with atrial fibrillation is predicted to drop the ATP/ADP ratio, thereby activating K ATP channels and leading to reduced refractoriness and promotion of atrial fibrillation. One might further speculate that enhanced metabolic sensitivity of K ATP channels in atrial myocytes might also be involved in the initiation of atrial fibrillation which occurs during periods of intense exercise or in cardiac surgical patients, often initiated
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In summary, Flagg et al provide another example of an atrial-ventricular gradient in the expression of a protein that is sure to have important consequences on differences in function between the atrium versus the ventricle. Because these results are confined to the mouse heart, it will be important to determine whether a similar molecular gradient exists in other species and in humans. Appreciation of chamber-specific differences in K ATP currents may provide new opportunities for treatment of conditions such as atrial fibrillation. 
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